Actinium Pharmaceuticals presented promising data for ATNM-400, a radioconjugate targeting a non-PSMA tumor antigen in prostate cancer and other tumors, using actinium-225. Additionally, Vitsgen Therapeutics disclosed preclinical results for [177Lu]PSMA-VG-01, a PSMA-targeted radiotheranostic for metastatic castration-resistant prostate cancer. Meanwhile, novel small molecule inhibitors including PKMYT1 and Aurora kinase B representatives have been patented and characterized, underscoring ongoing advances in targeted oncology agents.